Homologous Recombination: How Cells Repair DNA

Homologous recombination is one of the most fundamental DNA repair processes in biology, used by cells from bacteria to humans to fix dangerous breaks in their chromosomes by copying information from an intact, matching DNA molecule. It is also the engine behind the genetic shuffling that happens during sexual reproduction. The mechanism touches an enormous range of biology and medicine, from why certain cancers respond to specific drugs to why genome editing with CRISPR remains tricky for precise corrections.

How a Broken Chromosome Gets Fixed

The trigger for homologous recombination is almost always a double-strand break, where both rails of the DNA ladder snap. This is among the most dangerous types of DNA damage a cell can sustain, because a loose chromosome end left unrepaired can lead to mutations, chromosome rearrangements, or cell death. To fix it using homologous recombination, the cell first chews back one strand at each broken end, leaving long single-stranded tails. This step, called end resection, is carried out by a team of nucleases that degrade the strand running in one direction while leaving the other intact.

1PubMed Central. DNA end resection during homologous recombination

Those single-stranded tails then get coated by a protein called RAD51, which forms a filament along the DNA. This filament is the search engine of the process: it slides along nearby double-stranded DNA looking for a matching sequence. When it finds one, RAD51 physically pries apart the two strands of the intact donor molecule and threads the broken strand in between them, forming a structure called a displacement loop. Recent structural work has shown exactly how RAD51 accomplishes this: loops within the protein wedge themselves between the donor strands in a stepwise fashion, peeling them apart three nucleotides at a time and exposing each triplet for pairing with the invading strand.

2PubMed Central. Structural mechanism of strand exchange by the RAD51 filament

Once the broken strand is paired with its matching template, the cell’s DNA-copying machinery uses the intact molecule as a guide to fill in whatever was lost at the break. What happens next determines whether the two DNA molecules simply separate or physically swap arms. In one outcome, the intertwined strands form X-shaped structures called Holliday junctions, which are then cut by specialized enzymes called resolvases.

3PubMed Central. Holliday junction resolvases

Depending on how those junctions are cut, the result is either a crossover, where flanking DNA swaps between the two molecules, or a non-crossover, where the break is patched without any exchange. Interestingly, one key resolvase enzyme in many organisms prefers to cut junction intermediates before they fully mature into classical Holliday junctions, and its cutting orientation inherently produces crossovers.

4Molecular Cell. Mus81-Eme1 Resolves Holliday Junctions by Cleaving Intermediates that Precede Their Formation

The Role in Sexual Reproduction

If homologous recombination only fixed accidental damage, it would already be essential. But cells also use it on purpose during meiosis, the special cell division that produces eggs and sperm. Before meiotic cells divide, a protein called Spo11 deliberately slices the cell’s own DNA, creating hundreds of double-strand breaks across the genome.

5PubMed. Meiosis-specific DNA double-strand breaks are catalyzed by Spo11, a member of a widely conserved protein family

Spo11 is related to an ancient family of enzymes found even in archaea, hinting that this mechanism of deliberate breakage is extremely old.

6PubMed Central. Spo11 and the Formation of DNA Double-Strand Breaks in Meiosis

These intentional breaks are repaired using the matching chromosome inherited from the other parent as a template. That repair process generates crossovers, physically linking the two parental chromosomes at specific points along their length. Those crossover connections are not just a side effect; they are mechanically required to ensure that each egg or sperm receives the correct number of chromosomes. They also shuffle genetic material between the parental copies, which is why siblings who share the same parents are not genetically identical.

Meiotic and everyday (mitotic) recombination look similar at first glance, but their goals are different, and the molecular details reflect that. In meiosis, crossovers are the desired outcome, and the cell actively steers repair toward the classical double-Holliday-junction pathway that generates them. In dividing body cells, however, the goal is simply to fix the damage without rearranging anything. Accordingly, most mitotic repair uses a simpler route in which the broken strand copies a short stretch from the template, then detaches and re-anneals with its original partner, producing non-crossover outcomes almost exclusively.

7PubMed Central. Meiotic versus mitotic recombination: two different routes for double-strand break repair

Rescuing Stalled Replication Forks

Beyond repairing outright breaks, homologous recombination plays a quieter but equally critical role every time a cell copies its DNA. When a replication fork, the molecular machinery that unzips and copies the double helix, runs into an obstacle like a protein stuck on the DNA or a chemical lesion, it can stall or collapse. Left alone, a collapsed fork can become a double-strand break. Homologous recombination proteins step in both to protect the stalled fork from being degraded and to help restart copying once the obstacle is cleared.

8PubMed Central. Homologous recombination as a replication fork escort: fork-protection and recovery

Work in yeast has shown that the core recombination proteins Rad51 and Rad52 are needed to finish DNA replication when forks are deliberately blocked. Rather than restarting the stalled fork outright, these proteins often stabilize it until a fork coming from the opposite direction arrives and merges with it, completing the copy that way.

9PubMed Central. Homologous recombination and Mus81 promote replication completion in response to replication fork blockage

This fork-protection function is one reason mutations in recombination genes cause such widespread genomic instability: cells lose not just their ability to repair breaks but also their ability to cope with the everyday hiccups of DNA replication.

Bacteria Have Their Own Version

Homologous recombination is not unique to organisms with nuclei. Bacteria like E. coli use it heavily, though with different molecular players. The major bacterial pathway revolves around the RecBCD complex, a powerful helicase-nuclease that rapidly unwinds DNA at a break site and chews it up until it encounters a short signal sequence called Chi.

10PubMed Central. How RecBCD enzyme and Chi promote DNA break repair and recombination: a molecular biologist’s view

When RecBCD hits a Chi site, its behavior changes: it stops degrading the strand it was chewing and instead begins loading RecA (the bacterial equivalent of RAD51) onto the resulting single-stranded tail. From that point, the process parallels what happens in eukaryotes: the RecA-coated strand invades an intact copy of the genome, and the break is repaired using that copy as a template. This system is vital for bacterial survival because bacteria encounter replication-fork collapses frequently, and RecBCD-mediated recombination is their primary way of dealing with the damage.

When Recombination Fails, Cancer Can Follow

The connection between homologous recombination and cancer is among the most medically significant stories in modern oncology. The BRCA1 and BRCA2 genes, whose mutations dramatically raise the risk of breast and ovarian cancer, encode proteins that are central to the recombination process. BRCA2, for instance, directly loads RAD51 onto single-stranded DNA at break sites. Its C-terminal region is needed both for the strand-exchange step of recombination and for protecting stalled replication forks from being chewed up.

11Nature Communications. DNA binding and RAD51 engagement by the BRCA2 C-terminus orchestrate DNA repair and replication fork preservation

When either BRCA gene is knocked out, cells lose homologous recombination capacity and must rely on cruder, error-prone repair pathways. Errors pile up, and eventually the cells accumulate enough mutations to become cancerous.

This vulnerability, however, is also the tumor’s Achilles’ heel. Cancers that lack homologous recombination are dependent on other repair pathways to survive. PARP inhibitors exploit this dependence through a concept called synthetic lethality: PARP enzymes are involved in repairing a different class of DNA damage, and when both PARP activity and homologous recombination are knocked out simultaneously, the cancer cell cannot repair its DNA at all and dies.

12PubMed Central. PARP inhibitors: Synthetic lethality in the clinic

One model proposes that PARP inhibition causes the PARP-1 protein to become trapped on DNA, creating roadblocks for replication forks that would normally be cleared by homologous recombination.

13PubMed Central. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings

Recombination deficiency turns out to be far more common across cancer types than was initially appreciated. A large computational analysis of over 10,000 cancer patients found that the genomic scars left by failed recombination appear frequently across many tumor types, not just breast and ovarian cancers. The same analysis found that recombination-deficient tumors tend to have higher immune-cell infiltration, raising the possibility that these tumors could also respond to immunotherapy.

14Scientific Reports. Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types

Testing for recombination deficiency is increasingly becoming a clinical tool, with genomic scar scores being used alongside gene-mutation testing to guide treatment decisions.

15PubMed Central. Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types

How Tumors Fight Back Against PARP Inhibitors

PARP inhibitors have transformed care for patients with BRCA-mutated cancers, but resistance eventually emerges in many cases. The most common escape route, perhaps unsurprisingly, is restoring homologous recombination. Tumors achieve this in several ways. Reversion mutations can restore the broken BRCA gene’s reading frame, producing a partially functional protein again. In BRCA1-mutated cancers, the gene’s promoter can lose its silencing methylation marks, switching expression back on.

16Experimental & Molecular Medicine. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance

These reversion mutations are not limited to the BRCA genes themselves; they have been observed in other recombination pathway genes like RAD51C, RAD51D, and PALB2.

Other resistance mechanisms are more creative. Some tumors learn to protect their replication forks without recombination, or they suppress the competing error-prone repair pathway to reduce the toxic lesions PARP inhibitors create, or they simply pump the drug out of the cell more efficiently.

17PubMed Central. Mechanisms of resistance to PARP inhibitors – an evolving challenge in oncology

Understanding these escape routes is driving the development of second-line treatments and combination strategies designed to block resistance before it takes hold.

The CRISPR Problem

Homologous recombination sits at the heart of one of the biggest practical challenges in genome editing. When CRISPR-Cas9 cuts a target gene, the cell has two main options for repairing that cut. The quick-and-dirty option is non-homologous end joining, which simply glues the broken ends back together, often introducing small insertions or deletions in the process. The precise option is homology-directed repair, which uses a researcher-supplied DNA template to write a specific correction into the genome via homologous recombination.

The problem is that mammalian cells overwhelmingly prefer the quick-and-dirty route. Non-homologous end joining is active throughout the cell cycle and works faster, while homology-directed repair only operates during the S and G2 phases when a sister chromosome copy is available.

18PubMed Central. Methods Favoring Homology-Directed Repair Choice in Response to CRISPR/Cas9 Induced-Double Strand Breaks

Kinetic studies confirm that non-homologous end joining finishes repair before homology-directed repair can even get going at many cut sites, and its dominant editing patterns reduce the efficiency of the precise pathway.

19Nucleic Acids Research. Dynamics and competition of CRISPR–Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing

Researchers have attacked this competition from multiple angles. One approach directly inhibits a key enzyme in the end-joining pathway, DNA ligase IV, with a small molecule called Scr7. In mammalian cell lines and mice, this boosted precise editing efficiency by up to 19-fold for the genes tested.

20Nature Biotechnology. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining

Another strategy synchronizes cells in the phases of the cell cycle where recombination is active, using small molecules like nocodazole or docetaxel to hold cells in S or G2/M phase and thereby channel more cuts toward homology-directed repair.

21PubMed Central. Modulation of cell cycle increases CRISPR-mediated homology-directed DNA repair

Despite these advances, efficiently achieving precise edits without disrupting anything else remains one of the field’s open challenges, especially in non-dividing cells like neurons, where the cell-cycle window for recombination never opens.

Telomere Maintenance Without Telomerase

Most human cells shorten their chromosome tips, called telomeres, with each round of division. Cancer cells need to overcome this limit to keep dividing indefinitely, and about 85% of tumors do so by reactivating telomerase, the enzyme that extends telomeres. But a significant minority, roughly 10-15% of cancers, use a completely different strategy called alternative lengthening of telomeres, or ALT. This pathway relies on homologous recombination. Specifically, these tumors use a recombination-based mechanism called break-induced replication, in which one telomere invades and copies another telomere’s sequence to add length.

22Oxford Academic. The alternative lengthening of telomeres pathway through a DNA repair lens: mechanism and therapeutic opportunities

ALT-positive cancers are particularly common in certain sarcomas and brain tumors. Because they depend on recombination rather than telomerase, they are invisible to telomerase-targeted therapies but potentially vulnerable to drugs that interfere with recombination at telomeres.

When Recombination Happens in the Wrong Place

Homologous recombination normally works between perfectly matched sequences on partner chromosomes. But the genome is full of repeated sequences that look similar enough to fool the recombination machinery. When recombination occurs between two copies of a repetitive element that sit at different positions in the genome rather than at the same position on partner chromosomes, the result is called non-allelic homologous recombination, or NAHR. This process can delete, duplicate, or invert large stretches of DNA.

NAHR is implicated in numerous genetic disorders. Analyses of high-throughput sequencing data have detected NAHR-mediated deletions or duplications at over a hundred potential loci across just 44 individuals.

23PubMed Central. Detecting non-allelic homologous recombination from high-throughput sequencing data

One particularly widespread class of repeats involved are LINE elements, a type of mobile DNA that makes up a substantial fraction of the human genome. A genome-wide analysis found that LINE-LINE mediated NAHR is far more common than previously recognized, estimating that roughly 83% of the human genome is potentially susceptible to these events because of overlapping LINE pairs.

24Nucleic Acids Research. Genome-wide analyses of LINE–LINE-mediated nonallelic homologous recombination

NAHR is not all bad. Over evolutionary time, the gene duplications it creates have been a major source of new genes. Many gene families in our genome, clusters of related genes with slightly different functions, owe their existence to ancestral NAHR events that duplicated a gene, after which each copy drifted in its own evolutionary direction.

Recombination Declines With Age

One of the less intuitive consequences of homologous recombination biology is its connection to aging. As cells divide and age, their capacity for recombination drops. Studies in human cells have shown that homologous recombination efficiency can fall by up to 38-fold as cells approach the end of their replicative lifespan compared to young cells. As recombination wanes, cells increasingly default to the error-prone end-joining pathway, accumulating more mutations with each repair event.

25PubMed Central. Sirtuin 6 (SIRT6) rescues the decline of homologous recombination repair during replicative senescence

The same pattern shows up in aging yeast, where the decline has been traced to falling levels of key recombination proteins. Overexpressing Rad51 or Mre11 in old yeast cells reduced the accumulation of unrepaired breaks and largely restored normal repair.

26PubMed Central. Impaired cohesion and homologous recombination during replicative aging in budding yeast

This decline has real medical relevance beyond general aging. In female reproductive biology, expression of BRCA1, RAD51, MRE11, and ATM drops in aging oocytes in both mice and humans, and this decline in recombination-repair capacity has been linked to the age-related decrease in egg quality and fertility.

27PubMed Central. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans

Loss of Heterozygosity and Hidden Genetic Change

Recombination between matched chromosomes in ordinary body cells can produce a subtle but consequential genetic change called loss of heterozygosity. If you carry one normal copy and one mutated copy of a gene, mitotic recombination can, through crossing over or gene conversion, replace the normal copy with a duplicate of the mutant one, leaving the cell with two mutant copies. This process has been directly observed in organisms like the yeast Candida albicans, where researchers showed that loss of heterozygosity arose through both reciprocal crossing over and non-reciprocal gene conversion.

28PubMed. Loss of heterozygosity, by mitotic gene conversion and crossing over, causes strain-specific adenine mutants in constitutive diploid Candida albicans

In human cancer, loss of heterozygosity is one of the classic mechanisms by which cells lose their remaining good copy of a tumor-suppressor gene. A person who inherits one mutant BRCA1 allele, for example, still has one functional copy in every cell. Cancer develops when that second copy is lost, and mitotic recombination is one of the ways it can happen. The very repair process that normally protects the genome can, on rare occasions, become the instrument of its undoing.